Published through 2026-11-18 16:40 UTC · Automated cloud publishing.
Mounjaro Becomes Sweden's Best-Selling Drug, Impacting Optics Sector
Understand the event
According to a report from Optik (Sweden) published on November 17, 2026, the weight-loss medication Mounjaro has become Sweden’s best-selling drug. Data from E-hälsomyndigheten indicates that sales for the medication surpassed two billion kronor in September alone. The report highlights significant financial implications for patients, noting that individuals pay between 50,000 and 60,000 kronor annually out-of-pocket for the treatment. This surge in popularity and cost is described as having an impact on the optics sector, although the specific nature of this economic or operational effect is not detailed in the provided text. Additionally, the source mentions data from Kairos Future, but the excerpt cuts off before explaining what these findings indicate regarding the market or consumer behavior. No conflicting reports are present in the supplied material, so the chronology reflects only this single update.
AI-generated from reporting · updated 1 days ago
Reporting timeline
Follow the reporting for different perspectives.
- Optik (Sweden)Swedish weight-loss drug Mounjaro tops sales, impacting optics sector
Mounjaro has become Sweden’s best-selling medication, surpassing two billion kronor in September sales according to E-hälsomyndigheten. Patients pay 50,000–60,000 kronor annually out-of-pocket. Kairos Future data indicates seven percent of Swedes aged 16–74 have used Ozempic or similar weight-loss drugs. The EU approved the first oral weight-loss tablet this summer, while generic versions are available in India and Canada. PwC reports US households using these medications increased clothing purchases by nearly ten percent after six months. For the optical industry, EMA notes semaglutide can rarely cause NAION, a vision-threatening condition affecting up to one in 10,000 users. Additionally, changing body image may drive demand for new eyewear, though market impact depends on future pricing and studies.
Event coverage trend
Current coverage 5·Comparable peak 10(11-17 21:00)·Comparable change over 24 hours -51%
Trends compare continuously observed participants only; coverage may be narrower than the current total. Point, click or use arrow keys to inspect hourly values.